

Clinical Criteria updates

Summary: On May 20, 2022, August 19, 2022, and September 9, 2022, the Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for Empire BlueCross BlueShield HealthPlus (Empire). These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

- **The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.**
- **This notice is meant to inform the provider of new or revised criteria that has been adopted by Empire only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.**

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
February 23, 2023	*ING-CC-0219	Korsuva (difelikefalin acetate)	New
February 23, 2023	*ING-CC-0220	Xenpozyme (olipudase alfa)	New
February 23, 2023	*ING-CC-0221	Spevigo (spesolimab-sbzo)	New
February 23, 2023	ING-CC-0124	Keytruda (pembrolizumab)	Revised
February 23, 2023	ING-CC-0104	Levoleucovorin Agents	Revised
February 23, 2023	ING-CC-0100	Istodax (romidepsin)	Revised
February 23, 2023	ING-CC-0182	Iron Agents	Revised
February 23, 2023	*ING-CC-0075	Rituximab Agents for Non-Oncologic Indications	Revised
February 23, 2023	*ING-CC-0167	Rituximab Agents for Oncologic Indications Step Therapy	Revised
February 23, 2023	*ING-CC-0176	Beleodaq (belinostat)	Revised
February 23, 2023	ING-CC-0180	Monjuvi (tafasitamab-cxix)	Revised

* Availity, LLC is an independent company providing administrative support services on behalf of the health plan.

Effective date	Document number	Clinical Criteria title	New or revised
February 23, 2023	*ING-CC-0107	Bevacizumab for non-ophthalmologic indications	Revised
February 23, 2023	*ING-CC-0002	Colony Stimulating Factor Agents	Revised
February 23, 2023	ING-CC-0187	Breyanzi (lisocabtagene maraleucel)	Revised
February 23, 2023	ING-CC-0158	Enhertu (fam-trastuzumab deruxtecan-nxki)	Revised
February 23, 2023	ING-CC-0216	Opdualag (nivolumab and relatlimab-rmbw)	Revised
February 23, 2023	ING-CC-0196	Zynlonta (loncastuximab tesirine-lpyl)	Revised
February 23, 2023	ING-CC-0097	Vidaza (azacitidine)	Revised
February 23, 2023	*ING-CC-0142	Somatuline Depot (lanreotide)	Revised
February 23, 2023	*ING-CC-0058	Byngezia Pen, Sandostatin, or Sandostatin LAR (Octreotide)/ Octreotide Agents	Revised
February 23, 2023	*ING-CC-0082	Onpattro (patisiran)	Revised
February 23, 2023	*ING-CC-0084	Tegsedi (inotersen)	Revised
February 23, 2023	*ING-CC-0034	Hereditary Angioedema Agents	Revised
February 23, 2023	ING-CC-0019	Zoledronic Acid Agents	Revised
February 23, 2023	*ING-CC-0029	Dupixent (dupilumab)	Revised
February 23, 2023	*ING-CC-0035	Duopa (carbidopa and levodopa enteral suspension)	Revised
February 23, 2023	ING-CC-0140	Zulresso (brexanolone)	Revised
February 23, 2023	ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
February 23, 2023	ING-CC-0188	Imcivree (setmelanotide)	Revised
February 23, 2023	*ING-CC-0026	Testosterone Injectable	Revised
February 23, 2023	*ING-CC-0207	Vyvgart (efgartigimod alfa-fcab)	Revised
February 23, 2023	*ING-CC-0166	Trastuzumab Agents	Revised

Contact us:

Availity* Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. Go to Availity Essentials and select the appropriate payer space tile from the drop-down. Then select Chat with Payer and complete the pre-chat form to start your chat.

For additional support, visit the Contact Us section at the bottom of our provider website for the appropriate contact.



Email is the quickest and most direct way to receive important information from Empire BlueCross BlueShield HealthPlus.



To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3zqQdYB>).